title: Development of fatal tuberculosis in a patient with rheumatoid arthritis after three years of treatment with infliximab: comment on the article by Wolfe et al.
authors.forename: Esmeralda T H
authors.initials: ET
authors.lastname: Molenaar
authors.forename: Irene E M
authors.initials: IE
authors.lastname: Bultink
authors.forename: Ben A C
authors.initials: BA
authors.lastname: Dijkmans
authors.forename: Willem F
authors.initials: WF
authors.lastname: Lems
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D013902:Radiography, Thoracic; D014391:Tuberculosis, Miliary / Q000209:etiology* / Q000276:immunology / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab